Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'BROFAROMINE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 76 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Oosterbaan, DB; van Balkom, AJLM; Spinhoven, P; van Oppen, P; van Dyck, R
      Cognitive therapy versus moclobemide in social phobia: A controlled study

      CLINICAL PSYCHOLOGY & PSYCHOTHERAPY
    2. Connor, KM; Hidalgo, RB; Crockett, B; Malik, M; Katz, RJ; Davidson, JRT
      Predictors of treatment response in patients with posttraumatic stress disorder

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    3. Carruba, MO; Cuzzolaro, M; Riva, L; Bosello, O; Liberti, S; Castra, R; Dalle Grave, R; Santonastaso, P; Garosi, J; Nisoli, E
      Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    4. Van Ameringen, M; Mancini, C
      Pharmacotherapy of social anxiety disorder at the turn of the millennium

      PSYCHIATRIC CLINICS OF NORTH AMERICA
    5. Schneier, FR
      Treatment of social phobia with antidepressants

      JOURNAL OF CLINICAL PSYCHIATRY
    6. Bodkin, JA; Kwon, AE
      Selegiline and other atypical monoamine oxidase inhibitors in depression

      PSYCHIATRIC ANNALS
    7. Davidson, JRT
      Social anxiety disorder under scrutiny

      DEPRESSION AND ANXIETY
    8. van der Linden, GH; Stein, DJ; van Balkom, AJLM
      The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    9. Davidson, JRT
      Defining an appropriate management strategy for social anxiety disorder

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    10. Urichuk, LJ; Allison, K; Holt, A; Greenshaw, AJ; Baker, GB
      Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-termadministration

      JOURNAL OF AFFECTIVE DISORDERS
    11. Maki, Y; Inoue, T; Izumi, T; Muraki, I; Ito, K; Kitaichi, Y; Li, XB; Koyama, T
      Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing behavior in rats

      EUROPEAN JOURNAL OF PHARMACOLOGY
    12. Van Ameringen, M; Mancini, C; Oakman, JM; Farvolden, P
      Selective serotonin reuptake inhibitors in the treatment of social phobia - The emerging gold standard

      CNS DRUGS
    13. Mancini, C; Van Ameringen, M; Oakman, JM; Farvolden, P
      Serotonergic agents in the treatment of social phobia in children and adolescents: A case series

      DEPRESSION AND ANXIETY
    14. Wouters, J; Moureau, F; Evrard, G; Koenig, JJ; Jegham, S; George, P; Durant, F
      A reversible monoamine oxidase A inhibitor, befloxatone: Structural approach of its mechanism of action

      BIOORGANIC & MEDICINAL CHEMISTRY
    15. Rouillon, F
      Anxiety with depression: a treatment need

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    16. Westenberg, HGM
      Facing the challenge of social anxiety disorder

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    17. Lotufo-Neto, F; Trivedi, M; Thase, ME
      Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression

      NEUROPSYCHOPHARMACOLOGY
    18. Baker, GB; Urichuk, LJ; McKenna, KF; Kennedy, SH
      Metabolism of monoamine oxidase inhibitors

      CELLULAR AND MOLECULAR NEUROBIOLOGY
    19. Pande, AC; Davidson, JRT; Jefferson, JW; Janney, CA; Katzelnick, DJ; Weisler, RH; Greist, JH; Sutherland, SM
      Treatment of social phobia with gabapentin: A placebo-controlled study

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    20. Van Ameringen, M; Mancini, C; Oakman, JM
      Nefazodone in social phobia

      JOURNAL OF CLINICAL PSYCHIATRY
    21. Connor, KM; Davidson, JRT; Sutherland, S; Weisler, R
      Social phobia: Issues in assessment and management

      EPILEPSIA
    22. Stein, MB; Fyer, AJ; Davidson, JRT; Pollack, MH; Wiita, B
      Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study

      AMERICAN JOURNAL OF PSYCHIATRY
    23. GERARDY J; DRESSE A
      REGIONAL ACTION OF BROFAROMINE ON RAT-BRAIN MAO-A AND MAO-B

      Progress in neuro-psychopharmacology & biological psychiatry
    24. BOBES J
      HOW IS RECOVERY FROM SOCIAL ANXIETY DISORDER DEFINED

      The Journal of clinical psychiatry
    25. DAVIDSON JRT
      PHARMACOTHERAPY OF SOCIAL ANXIETY DISORDER

      The Journal of clinical psychiatry
    26. KATO M; KATAYAMA T; IWATA H; YAMAMURA M; MATSUOKA Y; NARITA H
      IN-VIVO CHARACTERIZATION OF T-794, A NOVEL REVERSIBLE INHIBITOR OF MONOAMINE OXIDASE-A, AS AN ANTIDEPRESSANT WITH A WIDE SAFETY MARGIN

      The Journal of pharmacology and experimental therapeutics
    27. SCHNEIER FR; GOETZ D; CAMPEAS R; FALLON B; MARSHALL R; LIEBOWITZ MR
      PLACEBO-CONTROLLED TRIAL OF MOCLOBEMIDE IN SOCIAL PHOBIA

      British Journal of Psychiatry
    28. LESTRA C; DAMATO T; GHAEMMAGHAMI C; PERRETLIAUDET A; BROYER M; RENAUD B; DALERY J; CHAMBA G
      BIOLOGICAL PARAMETERS IN MAJOR DEPRESSION - EFFECTS OF PAROXETINE, VILOXAZINE, MOCLOBEMIDE, AND ELECTROCONVULSIVE-THERAPY - RELATION TO EARLY CLINICAL OUTCOME

      Biological psychiatry
    29. Heimberg, RG; Liebowitz, MR; Hope, DA; Schneier, FR; Holt, CS; Welkowitz, LA; Juster, HR; Campeas, R; Bruch, MA; Cloitre, M; Fallon, B; Klein, DF
      Cognitive behavioral group therapy vs phenelzine therapy for social phobia- 12-week outcome

      ARCHIVES OF GENERAL PSYCHIATRY
    30. BERGSTROM M; WESTERBERG G; KIHLBERG T; LANGSTROM B
      SYNTHESIS OF SOME C-11 LABELED MAO-A INHIBITORS AND THEIR IN-VIVO UPTAKE KINETICS IN RHESUS-MONKEY BRAIN

      Nuclear medicine and biology
    31. MULLER H; MOLLER HJ
      METHODOLOGICAL CONSIDERATIONS AND EMPIRICAL-DATA TO THE ONSET OF EFFICACY OF ANTIDEPRESSANTS AND TO THE PREDICTION OF THERAPY OUTCOME

      European psychiatry
    32. PLENKER A; PUCHLER K; VOLZ HP
      THE EFFECTS OF RS-8359 ON CARDIOVASCULAR FUNCTION IN HEALTHY-SUBJECTSAND DEPRESSED-PATIENTS

      International clinical psychopharmacology
    33. VOLZ HP; GLEITER CH; MOLLER HJ
      BROFAROMINE VERSUS IMIPRAMINE IN INPATIENTS WITH MAJOR DEPRESSION - ACONTROLLED TRIAL

      Journal of affective disorders
    34. BARRETT JS; HOCHADEL TJ; MORALES RJ; ROHATAGI S; DEWITT KE; WATSON SK; DARNOW J; AZZARO AJ; DISANTO AR
      PRESSOR-RESPONSE TO TYRAMINE AFTER SINGLE 24-HOUR APPLICATION OF A SELEGILINE TRANSDERMAL SYSTEM IN HEALTHY-MALES

      Journal of clinical pharmacology
    35. REIMANN IW; JOBERT M; GLEITER CH; TURRI M; BIECK PR; HERRMANN WM
      DIFFERENT MODES OF DATA-PROCESSING AND STATISTICAL TESTING APPLIED TOTHE SAME SET OF PHARMACO-EEG RECORDINGS - EFFECTS ON THE EVALUATION OF A SELECTIVE AND THE REVERSIBLE MAO-A-INHIBITOR (BROFAROMINE)

      Neuropsychobiology
    36. VOLZ HP; GLEITER CH; WALDMEIER PC; STRUCK M; MOLLER HJ
      BROFAROMINE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE

      Journal of neural transmission
    37. KAGAYA T; KAJIWARA A; NAGATO S; AKASAKA K; KUBOTA A
      E2011, A NOVEL, SELECTIVE AND REVERSIBLE INHIBITOR OF MONOAMINE-OXIDASE TYPE-A

      The Journal of pharmacology and experimental therapeutics
    38. SLAAP BR; VANVLIET IM; WESTENBERG HGM; DENBOER JA
      MHPG AND HEART-RATE AS CORRELATES OF NONRESPONSE TO DRUG-THERAPY IN PANIC DISORDER PATIENTS - A PRELIMINARY-REPORT

      Psychopharmacology
    39. BULLER R
      REVERSIBLE INHIBITORS OF MONOAMINE-OXIDASE-A IN ANXIETY DISORDERS

      Clinical neuropharmacology
    40. VOLZ HP; MULLER H; MOLLER HJ
      ARE THERE ANY DIFFERENCES IN THE SAFETY AND EFFICACY OF BROFAROMINE AND IMIPRAMINE BETWEEN NON-ELDERLY AND ELDERLY PATIENTS WITH MAJOR DEPRESSION

      Neuropsychobiology
    41. VOLZ HP; MULLER H; STURM Y; PREUSSLER B; MOLLER HJ
      EFFECT OF INITIAL TREATMENT WITH ANTIDEPRESSANTS AS A PREDICTOR OF OUTCOME AFTER 8 WEEKS

      Psychiatry research
    42. SLAAP BR; VANVLIET IM; WESTENBERG HGM; DENBOER JA
      PHOBIC SYMPTOMS AS PREDICTORS OF NONRESPONSE TO DRUG-THERAPY IN PANICDISORDER PATIENTS (A PRELIMINARY-REPORT)

      Journal of affective disorders
    43. FAHLEN T
      PERSONALITY-TRAITS IN SOCIAL PHOBIA .2. CHANGES DURING DRUG-TREATMENT

      The Journal of clinical psychiatry
    44. PATAT A; BERLIN I; DURRIEU G; ARMAND P; FITOUSSI S; MOLINIER P; CAILLE P
      PRESSER EFFECT OF ORAL TYRAMINE DURING TREATMENT WITH BEFLOXATONE, A NEW REVERSIBLE MONOAMINE OXIDASE-A INHIBITOR, IN HEALTHY-SUBJECTS

      Journal of clinical pharmacology
    45. FAHLEN T; NILSSON HL; BORG K; HUMBLE M; PAULI U
      SOCIAL PHOBIA - THE CLINICAL EFFICACY AND TOLERABILITY OF THE MONOAMINE OXIDASE-A AND SEROTONIN UPTAKE INHIBITOR BROFAROMINE - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY

      Acta psychiatrica Scandinavica
    46. FINBERG JPM
      PHARMACOLOGY OF REVERSIBLE AND SELECTIVE INHIBITORS OF MONOAMINE-OXIDASE TYPE-A

      Acta psychiatrica Scandinavica
    47. PRIEST RG; GIMBRETT R; ROBERTS W; STEINERT J
      REVERSIBLE AND SELECTIVE INHIBITORS OF MONOAMINE-OXIDASE-A IN MENTAL AND OTHER DISORDERS

      Acta psychiatrica Scandinavica
    48. BAKER DG; DIAMOND BI; GILLETTE G; HAMNER M; KATZELNICK D; KELLER T; MELLMAN TA; PONTIUS E; ROSENTHAL M; TUCKER P; VANDERKOLK BA; KATZ R
      A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY OF BROFAROMINE IN THE TREATMENT OF POSTTRAUMATIC-STRESS-DISORDER

      Psychopharmacology
    49. DAVIS BA; KENNEDY SH; DSOUZA J; DURDEN DA; GOLDBLOOM DS; BOULTON AA
      CORRELATIONS OF PLASMA AND URINARY PHENYLACETIC ACID AND PHENYLETHYLAMINE CONCENTRATIONS WITH EATING BEHAVIOR AND MOOD RATING SCORES IN BROFAROMINE-TREATED WOMEN WITH BULIMIA-NERVOSA

      Journal of psychiatry & neuroscience
    50. KATZ R; LOTT MH; ARBUS P; CROCQ L; HERLOBSEN P; LINGJAERDE O; LOPEZ G; LOUGHREY GC; MACFARLANE DJ; MCIVOR R; MEHLUM L; NUGENT D; TURNER SW; WEISAETH L; YULE W
      PHARMACOTHERAPY OF POSTTRAUMATIC-STRESS-DISORDER WITH A NOVEL PSYCHOTROPIC

      Anxiety
    51. FANKHAUSER C; CHARIERAS T; CAILLE D; ROVEI V
      INTERACTION OF MAO INHIBITORS AND DIETARY TYRAMINE - A NEW EXPERIMENTAL-MODEL IN THE CONSCIOUS RAT

      Journal of pharmacological and toxicological methods
    52. RAMAEKERS JG; VANVEGGEL LMA; OHANLON JF
      A CROSS-STUDY COMPARISON OF THE EFFECTS OF MOCLOBEMIDE AND BROFAROMINE ON ACTUAL DRIVING PERFORMANCE AND ESTIMATED SLEEP

      Clinical neuropharmacology
    53. GLEITER CH; MUHLBAUER B; SCHULZ RM; NILSSON E; ANTONIN KH; BIECK PR
      MONOAMINE-OXIDASE INHIBITION BY THE MAO-A INHIBITORS BROFAROMINE AND CLORGYLINE IN HEALTHY-VOLUNTEERS

      Journal of neural transmission
    54. DENBOER JA; VANVLIET IM; WESTENBERG HGM
      RECENT ADVANCES IN THE PSYCHOPHARMACOLOGY OF SOCIAL PHOBIA

      Progress in neuro-psychopharmacology & biological psychiatry
    55. VERHOEVEN WMA
      BROFAROMINE IN ENDOGENOUS-DEPRESSION

      Progress in neuro-psychopharmacology & biological psychiatry
    56. CHOUINARD G; SAXENA BM; NAIR NPV; KUTCHER SP; BAKISH D; BRADWEJN J; KENNEDY SH; SHARMA V; REMICK RA; KUKHAMOHAMAD SA; BELANGER MC; SNAITH J; BEAUCLAIR L; POHLMANN H; DSOUZA J
      A CANADIAN MULTICENTER PLACEBO-CONTROLLED STUDY OF A FIXED-DOSE OF BROFAROMINE, A REVERSIBLE SELECTIVE MAO-A INHIBITOR, IN THE TREATMENT OFMAJOR DEPRESSION

      Journal of affective disorders
    57. VOLZ HP; FALTUS F; MAGYAR I; MOLLER HJ
      BROFAROMINE IN TREATMENT-RESISTANT DEPRESSED-PATIENTS - A COMPARATIVETRIAL VERSUS TRANYLCYPROMINE

      Journal of affective disorders
    58. HOENCAMP E; HAFFMANS PMJ; DIJKEN WA; HOOGDUIN CAL; NOLEN WA; VANDYCK R
      BROFAROMINE VERSUS LITHIUM ADDITION TO MAPROTILINE - A DOUBLE-BLIND-STUDY IN MAPROTILINE REFRACTORY DEPRESSED OUTPATIENTS

      Journal of affective disorders
    59. HOHAGEN F; MAYER G; MENCHE A; RIEMANN D; VOLK S; MEIEREWERT KH; BERGER M
      TREATMENT OF NARCOLEPSY CATAPLEXY SYNDROME WITH THE NEW SELECTIVE ANDREVERSIBLE MAO-A INHIBITOR BROFAROMINE - A PILOT-STUDY

      Journal of sleep research
    60. KERR JS; FAIRWEATHER DB; HINDMARCH I
      THE EFFECTS OF BROFAROMINE ALONE AND IN CONJUNCTION WITH ALCOHOL ON COGNITIVE FUNCTION, PSYCHOMOTOR PERFORMANCE, MOOD AND SLEEP IN HEALTHY-VOLUNTEERS

      Human psychopharmacology
    61. JEDRYCHOWSKI M; FEIFEL N; BIECK PR; SCHMIDT EK
      METABOLISM OF THE NEW MAO-A INHIBITOR BROFAROMINE IN POOR AND EXTENSIVE METABOLIZERS OF DEBRISOQUINE

      Journal of pharmaceutical and biomedical analysis
    62. KENNEDY SH; DAVIS BA; BROWN GM; FORD CG; DSOUZA J
      EFFECTS OF CHRONIC BROFAROMINE ADMINISTRATION ON BIOGENIC-AMINES INCLUDING SULPHATOXYMELATONIN AND ACID METABOLITES IN PATIENTS WITH BULIMIA-NERVOSA

      Neurochemical research
    63. ANDERSON MC; HASAN F; MCCRODDEN JM; TIPTON KF
      MONOAMINE-OXIDASE INHIBITORS AND THE CHEESE EFFECT

      Neurochemical research
    64. LAVIAN G; FINBERG JPM; YOUDIM MBH
      THE ADVENT OF A NEW-GENERATION OF MONOAMINE-OXIDASE INHIBITOR ANTIDEPRESSANTS - PHARMACOLOGICAL STUDIES WITH MOCLOBEMIDE AND BROFAROMINE

      Clinical neuropharmacology
    65. BIECK PR; ANTONIN KH; SCHMIDT E
      CLINICAL-PHARMACOLOGY OF REVERSIBLE MONOAMINE OXIDASE-A INHIBITORS

      Clinical neuropharmacology
    66. CALLINGHAM BA
      DRUG-INTERACTIONS WITH REVERSIBLE MONOAMINE OXIDASE-A INHIBITORS

      Clinical neuropharmacology
    67. NOLEN WA; HOENCAMP E; BOUVY PF; HAFFMANS PMJ
      REVERSIBLE MONOAMINE OXIDASE-A INHIBITORS IN RESISTANT MAJOR DEPRESSION

      Clinical neuropharmacology
    68. BAKISH D; SAXENA BM; BOWEN R; DSOUZA J
      REVERSIBLE MONOAMINE OXIDASE-A INHIBITORS IN PANIC DISORDER

      Clinical neuropharmacology
    69. DAVIS BA; KENNEDY SH; DURDEN DA; DSOUZA J; GOLDBLOOM DS; BOULTON AA
      THE EFFECT OF THE MAO-A SELECTIVE INHIBITOR BROFAROMINE ON THE PLASMAAND URINE CONCENTRATIONS OF SOME BIOGENIC-AMINES AND THEIR ACIDIC METABOLITES IN BULIMIA-NERVOSA

      Progress in neuro-psychopharmacology & biological psychiatry
    70. NOLEN WA; HAFFMANS PMJ; BOUVY PF; DUIVENVOORDEN HJ
      MONOAMINE-OXIDASE INHIBITORS IN RESISTANT MAJOR DEPRESSION - A DOUBLE-BLIND COMPARISON OF BROFAROMINE AND TRANYLCYPROMINE IN PATIENTS RESISTANT TO TRICYCLIC ANTIDEPRESSANTS

      Journal of affective disorders
    71. FEIFEL N; KUCHER K; FUCHS L; JEDRYCHOWSKI M; SCHMIDT E; ANTONIN KH; BIECK PR; GLEITER CH
      ROLE OF CYTOCHROME-P4502D6 IN THE METABOLISM OF BROFAROMINE - A NEW SELECTIVE MAO-A INHIBITOR

      European Journal of Clinical Pharmacology
    72. COLZI A; DAGOSTINI F; CESURA AM; BORRONI E; DAPRADA M
      MONOAMINE OXIDASE-A INHIBITORS AND DOPAMINE METABOLISM IN RAT CAUDATUS - EVIDENCE THAT AN INCREASED CYTOSOLIC LEVEL OF DOPAMINE DISPLACES REVERSIBLE MONOAMINE OXIDASE-A INHIBITORS INVIVO

      The Journal of pharmacology and experimental therapeutics
    73. VANVLIET IM; WESTENBERG HGM; DENBOER JA
      MAO INHIBITORS IN PANIC DISORDER - CLINICAL EFFECTS OF TREATMENT WITHBROFAROMINE - A DOUBLE BLIND PLACEBO CONTROLLED STUDY

      Psychopharmacology
    74. WHITE HL; SCATES PW
      MECHANISM OF MONOAMINE OXIDASE-A INHIBITION BY BW-1370U87

      Drug development research
    75. JONESHUMBLE SA; NORTON RM; WHITE HL; COOPER BR
      BW-1370U87, A NEW MONOAMINE OXIDASE-A INHIBITOR - EFFECTS ON BIOGENIC-AMINE NEUROTRANSMITTER AND METABOLITE LEVELS IN RAT-BRAIN

      Drug development research
    76. CARROLL M; BEEK O
      BLOOD-PRESSURE EFFECTS OF MONOAMINE-OXIDASE INHIBITORS IN RESPONSE TOORALLY-ADMINISTERED TYRAMINE IN THE RAT

      Drug development research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/08/20 alle ore 04:37:18